Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Alzheimer Disease D000544 76 associated lipids
Anorexia D000855 8 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Ataxia D001259 20 associated lipids
Urinary Bladder Diseases D001745 4 associated lipids
Body Weight D001835 333 associated lipids
Bradycardia D001919 13 associated lipids
Brain Concussion D001924 5 associated lipids
Brain Damage, Chronic D001925 6 associated lipids
Brain Edema D001929 20 associated lipids
Breast Neoplasms D001943 24 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bulimia D002032 3 associated lipids
Cardiomyopathy, Dilated D002311 15 associated lipids
Catalepsy D002375 30 associated lipids
Celiac Disease D002446 16 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Iuvone T et al. Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. 2007 J. Mol. Med. pmid:17639288
Eisenstein TK et al. Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. 2007 J. Neuroimmunol. pmid:17640739
Pakdeechote P et al. Cannabinoids inhibit noradrenergic and purinergic sympathetic cotransmission in the rat isolated mesenteric arterial bed. 2007 Br. J. Pharmacol. pmid:17641668
Castelli MP et al. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2. 2007 Eur. J. Pharmacol. pmid:17644084
Cippitelli A et al. The anandamide transport inhibitor AM404 reduces ethanol self-administration. 2007 Eur. J. Neurosci. pmid:17650118
Romano MR and Lograno MD Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle. 2007 Invest. Ophthalmol. Vis. Sci. pmid:17652738
Mulè F et al. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. 2007 Pharmacol. Res. pmid:17656103
Després JP The endocannabinoid system: a new target for the regulation of energy balance and metabolism. 2007 Crit Pathw Cardiol pmid:17667864
Wise LE et al. Evaluation of fatty acid amides in the carrageenan-induced paw edema model. 2008 Neuropharmacology pmid:17675189
Thors L et al. Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake. 2007 Br. J. Pharmacol. pmid:17676056
Oz M et al. The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes. 2007 J. Pharmacol. Exp. Ther. pmid:17682128
Gorzalka BB et al. Endocannabinoid modulation of male rat sexual behavior. 2008 Psychopharmacology (Berl.) pmid:17694389
Evans RM et al. Chronic exposure of sensory neurones to increased levels of nerve growth factor modulates CB1/TRPV1 receptor crosstalk. 2007 Br. J. Pharmacol. pmid:17700720
Wheal AJ et al. Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. 2007 Br. J. Pharmacol. pmid:17700721
Matias I et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. 2007 Br. J. Pharmacol. pmid:17704823
Herradón E et al. Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. 2007 Br. J. Pharmacol. pmid:17704831
Smid SD et al. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. 2007 Eur. J. Pharmacol. pmid:17706636
Moreira FA et al. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. 2008 Neuropharmacology pmid:17709120
Hanus LO Discovery and isolation of anandamide and other endocannabinoids. 2007 Chem. Biodivers. pmid:17712821
Okamoto Y et al. Biosynthetic pathways of the endocannabinoid anandamide. 2007 Chem. Biodivers. pmid:17712822
Yuece B et al. Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. 2007 Neurogastroenterol. Motil. pmid:17727394
Cisneros JA et al. Structure-activity relationship of a series of inhibitors of monoacylglycerol hydrolysis--comparison with effects upon fatty acid amide hydrolase. 2007 J. Med. Chem. pmid:17764163
Rueda-Orozco PE et al. A potential function of endocannabinoids in the selection of a navigation strategy by rats. 2008 Psychopharmacology (Berl.) pmid:17805517
Bourne C et al. Novel, potent THC/anandamide (hybrid) analogs. 2007 Bioorg. Med. Chem. pmid:17827022
Yang YY et al. Role of Ca2+-dependent potassium channels in in vitro anandamide-mediated mesenteric vasorelaxation in rats with biliary cirrhosis. 2007 Liver Int. pmid:17845532
Ghasemi M et al. Anandamide improves the impaired nitric oxide-mediated neurogenic relaxation of the corpus cavernosum in diabetic rats: involvement of cannabinoid CB1 and vanilloid VR1 receptors. 2007 BJU Int. pmid:17850365
Ryberg E et al. The orphan receptor GPR55 is a novel cannabinoid receptor. 2007 Br. J. Pharmacol. pmid:17876302
Joshi SR Endocannabinoid system--a novel target for cardiometabolic risk. 2007 J Assoc Physicians India pmid:17879500
Mitchell VA et al. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. 2007 Clin. Exp. Pharmacol. Physiol. pmid:17880375
Nakata M and Yada T Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. 2008 Regul. Pept. pmid:17884194
Sakamoto Y et al. Clinical responses and improvement of some laboratory parameters following polymyxin B-immobilized fiber treatment in septic shock. 2007 Sep-Oct ASAIO J. pmid:17885340
Morgese MG et al. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. 2007 Exp. Neurol. pmid:17900568
Hillard CJ et al. Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase. 2007 J. Mol. Neurosci. pmid:17901541
Opitz CA et al. Production of the endocannabinoids anandamide and 2-arachidonoylglycerol by endothelial progenitor cells. 2007 FEBS Lett. pmid:17904123
Scherma M et al. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. 2008 Neuropharmacology pmid:17904589
Sun Y et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. 2007 Br. J. Pharmacol. pmid:17906680
Degenhardt BF et al. Role of osteopathic manipulative treatment in altering pain biomarkers: a pilot study. 2007 J Am Osteopath Assoc pmid:17908831
Xu H et al. Functional effects of nonsynonymous polymorphisms in the human TRPV1 gene. 2007 Am. J. Physiol. Renal Physiol. pmid:17913835
Kim SR et al. Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: neuroprotection versus neurotoxicity. 2007 Mol. Neurobiol. pmid:17917113
Rubino T et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. 2008 Cereb. Cortex pmid:17921459
Hornig B Endothelial vasodilatory cannabinoid receptor in the human pulmonary artery: a future option in the therapy of pulmonary hypertension? 2007 J. Hypertens. pmid:17921811
Kozłowska H et al. Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery. 2007 J. Hypertens. pmid:17921818
Athanasiou A et al. Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. 2007 Biochem. Biophys. Res. Commun. pmid:17931597
Astarita G et al. Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain. 2008 J. Lipid Res. pmid:17957091
Kracke GR et al. The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes. 2007 Naunyn Schmiedebergs Arch. Pharmacol. pmid:17960365
Correa F et al. Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E(2). 2008 Biochem. J. pmid:17961121
Bentzen PJ and Lang F Effect of anandamide on erythrocyte survival. 2007 Cell. Physiol. Biochem. pmid:17975305
Mukhopadhyay S and Tulis DA Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke. 2007 Cardiovasc Hematol Agents Med Chem pmid:17979695
Dainese E et al. Modulation of the endocannabinoid system by lipid rafts. 2007 Curr. Med. Chem. pmid:17979719
Muccioli GG and Stella N An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain. 2008 Anal. Biochem. pmid:17981259
Thiemann G et al. The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. 2008 Behav. Brain Res. pmid:17988751
Xiong W et al. Anandamide inhibition of 5-HT3A receptors varies with receptor density and desensitization. 2008 Mol. Pharmacol. pmid:17993512
Rossi C et al. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. 2008 Eur. J. Clin. Pharmacol. pmid:18004553
Ortar G et al. New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. 2007 J. Med. Chem. pmid:18027904
Lemak MS et al. Cannabinoid regulation in identified synapse of terrestrial snail. 2007 Eur. J. Neurosci. pmid:18028114
Bjursell M et al. Acutely reduced locomotor activity is a major contributor to Western diet-induced obesity in mice. 2008 Am. J. Physiol. Endocrinol. Metab. pmid:18029443
Béquet F et al. CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus. 2007 Eur. J. Neurosci. pmid:18052990
Hill MN et al. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus. 2008 Hippocampus pmid:18058925
Williams MA et al. The group IV afferent neuron expresses multiple receptor alterations in cardiomyopathyic rats: evidence at the cannabinoid CB1 receptor. 2008 J. Physiol. (Lond.) pmid:18063665
Egertová M et al. Localization of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) expression in mouse brain: A new perspective on N-acylethanolamines as neural signaling molecules. 2008 J. Comp. Neurol. pmid:18067139
Rettori V et al. Endocannabinoids in TNF-alpha and ethanol actions. 2007 Neuroimmunomodulation pmid:18073513
Adermark L and Lovinger DM Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step. 2007 Proc. Natl. Acad. Sci. U.S.A. pmid:18077376
Imming P Fatty pain cures. 2007 Chem. Biol. pmid:18096498
Blankman JL et al. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. 2007 Chem. Biol. pmid:18096503
King AR et al. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. 2007 Chem. Biol. pmid:18096504
DeMorrow S et al. Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation. 2008 Am. J. Physiol. Gastrointest. Liver Physiol. pmid:18096608
Paradisi A et al. Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. 2008 J. Biol. Chem. pmid:18165231
Burstein S The elmiric acids: biologically active anandamide analogs. 2008 Neuropharmacology pmid:18187165
Butt C et al. Endogenous cannabinoid anandamide inhibits nicotinic acetylcholine receptor function in mouse thalamic synaptosomes. 2008 J. Neurochem. pmid:18194436
Sakamoto Y et al. Effectiveness of continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter after polymyxin B-immobilized fiber column therapy of septic shock. 2008 Jan-Feb ASAIO J. pmid:18204329
Maccarrone M et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. 2008 Nat. Neurosci. pmid:18204441
Oddi S et al. Evidence for the intracellular accumulation of anandamide in adiposomes. 2008 Cell. Mol. Life Sci. pmid:18213445
Di Marzo V et al. The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. 2008 Br. J. Pharmacol. pmid:18223666
Simon GM and Cravatt BF Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. 2008 J. Biol. Chem. pmid:18227059
Baldassano S et al. Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle. 2008 Eur. J. Pharmacol. pmid:18234188
Starowicz KM et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. 2008 Obesity (Silver Spring) pmid:18239598
Jackson SN et al. Volatile anesthetics and endogenous cannabinoid anandamide have additive and independent inhibitory effects on alpha(7)-nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. 2008 Eur. J. Pharmacol. pmid:18242598
Gertsch J Immunomodulatory lipids in plants: plant fatty acid amides and the human endocannabinoid system. 2008 Planta Med. pmid:18275004
Oláh M et al. The role of endocannabinoids in the regulation of luteinizing hormone and prolactin release. Differences between the effects of AEA and 2AG. 2008 Mol. Cell. Endocrinol. pmid:18308464
Potvin S et al. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. 2008 J. Psychopharmacol. (Oxford) pmid:18308802
Hill MN et al. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. 2008 Pharmacopsychiatry pmid:18311684
Fezza F et al. Characterization of biotin-anandamide, a novel tool for the visualization of anandamide accumulation. 2008 J. Lipid Res. pmid:18316795
Kurtuncu M et al. Effects of cocaine in 5-lipoxygenase-deficient mice. 2008 J Neural Transm pmid:18327533
Habayeb OM et al. Plasma anandamide concentration and pregnancy outcome in women with threatened miscarriage. 2008 JAMA pmid:18334688
Migliarini B and Carnevali O Anandamide modulates growth and lipid metabolism in the zebrafish Danio rerio. 2008 Mol. Cell. Endocrinol. pmid:18342434
De Oliveira Alvares L et al. Differential role of the hippocampal endocannabinoid system in the memory consolidation and retrieval mechanisms. 2008 Neurobiol Learn Mem pmid:18342551
Palkovits M et al. Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. 2008 Neuroscience pmid:18343585
Engeli S et al. Peripheral endocannabinoid system activity in patients treated with sibutramine. 2008 Obesity (Silver Spring) pmid:18356837
Rubio M et al. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. 2008 Neuropharmacology pmid:18371990
Evans RM et al. Modulation of sensory neuron potassium conductances by anandamide indicates roles for metabolites. 2008 Br. J. Pharmacol. pmid:18376419
Hegde VL et al. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. 2008 Mol. Pharmacol. pmid:18388242
Di Marzo V and Maccarrone M FAAH and anandamide: is 2-AG really the odd one out? 2008 Trends Pharmacol. Sci. pmid:18394720
Kaufmann I et al. Anandamide and neutrophil function in patients with fibromyalgia. 2008 Psychoneuroendocrinology pmid:18395993
Solinas M et al. The endocannabinoid system in brain reward processes. 2008 Br. J. Pharmacol. pmid:18414385
Richardson D et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. 2008 Arthritis Res. Ther. pmid:18416822
Ortar G et al. New tetrazole-based selective anandamide uptake inhibitors. 2008 Bioorg. Med. Chem. Lett. pmid:18424134
Bisogno T Endogenous cannabinoids: structure and metabolism. 2008 J. Neuroendocrinol. pmid:18426492
Capasso R and Izzo AA Gastrointestinal regulation of food intake: general aspects and focus on anandamide and oleoylethanolamide. 2008 J. Neuroendocrinol. pmid:18426498
Ahn K et al. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. 2008 Chem. Rev. pmid:18429637
Gonçalves P et al. Lack of a significant effect of cannabinoids upon the uptake of 2-deoxy-D-glucose by Caco-2 cells. 2008 Pharmacology pmid:18431074